$2.02
(Market cap
$400 Mln
Recently Viewed
Clear AllMarket cap
$400 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
3
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
-0.1 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
1
Debt to Equity
--
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
45,673,839
CFO
$-1,805.09 Mln
EBITDA
$-1,648.80 Mln
Net Profit
$-1,873.97 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
| -- | -- | -- | 26.1 | -- | 8.2 | -- |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2021
|
2020
|
2019
|
|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
| -69.7 | 6.0 | -30.8 |
|
S&P Small-Cap 600
| 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
LogicBio Therapeutics (LOGC)
|
8.7 | 399.7 | 0.0 | -29.0 | -- | -20.4 | -- | 3.0 |
| 4.0 | 455.5 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.9 | |
| 19.5 | 1,263.0 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 7.5 | |
| 14.0 | 2,706.5 | 550.0 | 458.1 | -3.3 | 45.9 | 5.9 | 2.2 | |
| 5.3 | 1,177.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.6 | 2,154.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.7 | |
| 16.8 | 1,224.6 | 403.3 | 22.8 | 3,081.6 | 9.1 | 433.5 | 4.4 | |
| 3.9 | 687.9 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.7 | |
| 17.9 | 445.5 | 4.8 | 53.5 | -- | 12.2 | 10.8 | 1.2 | |
| 21.9 | 2,732.0 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.8 |
ContextLogic Holdings Inc. focuses on seeking to develop and grow a de novo business and finance potential future bolt-on acquisitions of assets or businesses. The company was incorporated in 2010 and is headquartered in Oakland, California.
Pres, CEO & Director
Mr. Frederic Chereau M.B.A.
Pres, CEO & Director
Mr. Frederic Chereau M.B.A.
Headquarters
Oakland, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of LogicBio Therapeutics Inc (LOGC) is $8.70 (NASDAQ) as of 23-Apr-2026 11:25 EDT. LogicBio Therapeutics Inc (LOGC) has given a return of 26.09% in the last 1 years.
Since, TTM earnings of LogicBio Therapeutics Inc (LOGC) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
--
|
--
|
|
2024
|
-2.46
|
1.22
|
|
2023
|
--
|
--
|
|
2022
|
--
|
--
|
|
2021
|
-0.21
|
0.09
|
The 52-week high and low of LogicBio Therapeutics Inc (LOGC) are Rs 8.80 and Rs 6.57 as of 23-Apr-2026.
LogicBio Therapeutics Inc (LOGC) has a market capitalisation of $ 400 Mln as on 17-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in LogicBio Therapeutics Inc (LOGC), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.